Ballentine Partners’s iShares Biotechnology ETF IBB Stock Holding History

Ballentine Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	+1,080	New	+$186K	﹤0.01%	999
2018 Q1	–	Sell	-654	Closed	-$70K	–	373
2017 Q4	$70K	Sell	654 -21	-3%	-$2.25K	﹤0.01%	362
2017 Q3	$75K	Hold	675	–	–	﹤0.01%	392
2017 Q2	$73K	Buy	+675	New	+$66.5K	0.01%	391
2017 Q1	–	Sell	-870	Closed	-$77K	–	264
2016 Q4	$77K	Buy	+870	New	+$79.2K	0.01%	183

Other funds holding IBB

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

FNFDCM

Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

RFA

Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

SCA

Southern Capital Advisors Jackson, Tennessee $239M AUM 22.42% 1-Year Est. Return

Ballentine Partners's IBB Position: Q2 2026 in Review

Ballentine Partners opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,080 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #999 among its holdings. This is a return to the name: Ballentine Partners previously reported a position in IBB as recently as Q4 2017.

Ballentine Partners first reported a position in IBB in Q4 2016 and has held it in 5 quarters since. 158 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Ballentine Partners held 1,080 shares of iShares Biotechnology ETF worth $205K as of Q2 2026.
iShares Biotechnology ETF was a new Ballentine Partners position in Q2 2026.
iShares Biotechnology ETF made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #999 holding.
Ballentine Partners first reported a position in iShares Biotechnology ETF in Q4 2016 and has held it in 5 quarters since.
158 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.